<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199000</url>
  </required_header>
  <id_info>
    <org_study_id>19-005187</org_study_id>
    <secondary_id>U54NS115198-01</secondary_id>
    <nct_id>NCT04199000</nct_id>
  </id_info>
  <brief_title>Clinical and Basic Investigations Into Congenital Disorders of Glycosylation</brief_title>
  <official_title>Clinical and Basic Investigations Into Congenital Disorders of Glycosylation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tulane University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanford-Burnham Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study the natural history of congenital disorders of&#xD;
      glycosylation and its causes and treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are conducting a natural history study of patients with congenital&#xD;
      disorders of glycosylation (CDG). The study will look into the progression of the disease&#xD;
      amongst the participants and also look at the clinical symptoms and how they vary amongst&#xD;
      different diseased population groups. The participants will be asked to fill out&#xD;
      questionnaires either on their own or with a provider that will grade the severity of disease&#xD;
      and document symptoms and diet. Participants will have an opportunity to submit blood, urine,&#xD;
      and stool samples that will be tested for biomarkers for CDG.&#xD;
&#xD;
      Participants will also complete dietary food records, physical exams, CDG scores, and the&#xD;
      PROMIS questionnaires to assess disease progression and severity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Indicators of Disease Severity and Progression - organ system involvement</measure>
    <time_frame>Length of study, up to 5 years</time_frame>
    <description>Establish the prevalence and severity of specific morbid indicators of disease severity through use of the Nijmegen Progression CDG rating scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Indicators of Disease Severity and Progression - degree of cognitive disability</measure>
    <time_frame>Length of study, up to 5 years</time_frame>
    <description>Establish the prevalence and severity of specific morbid indicators of disease severity through use of the Nijmegen Progression CDG rating scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Indicators of Disease Severity and Progression - case-fatality</measure>
    <time_frame>Length of study, up to 5 years</time_frame>
    <description>Establish the prevalence and severity of specific morbid indicators of disease severity through use of the Nijmegen Progression CDG rating scale.</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Congenital Disorders of Glycosylation</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool, urine, and blood can be retained for biomarker testing. DNA may be a part of this&#xD;
      testing in the future.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients included in the study must have genetic confirmation of a primary congenital&#xD;
        disorder of glycosylation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with congenital disorders of glycosylation based on genetic&#xD;
             confirmatory testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients without congenital disorders of glycosylation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Morava-Kozicz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Morava-Kozicz, PhD, MD</last_name>
    <phone>507-266-2967</phone>
    <email>morava-kozicz.eva@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaitlin Schwartz, B.S.</last_name>
    <phone>507-293-9114</phone>
    <email>schwartz.kaitlin@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Austin Larson, MD</last_name>
      <phone>303-724-3632</phone>
      <email>Austin.Larson@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Bridget Flanders, BA</last_name>
      <phone>720-777-4309</phone>
      <email>Bridget.Flanders@childrenscolorado.org</email>
    </contact_backup>
    <investigator>
      <last_name>Austin Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University Medical School</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Anderrson, MD</last_name>
      <phone>504-988-5101</phone>
      <email>handers@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Hans Anderrson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard Berry, MD</last_name>
      <phone>617-355-6394</phone>
      <email>Gerard.Berry@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Danielle Terek</last_name>
      <phone>617-355-7346</phone>
      <email>Danielle.Terek@childrens.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gerard Berry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyriakie Sarafoglou, MD</last_name>
      <phone>612-624-5409</phone>
      <email>saraf010@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Paige Hill</last_name>
      <phone>612-624-8672</phone>
      <email>hillx615@umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kyriakie Sarfoglou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Morava-Kozicz, MD, PhD</last_name>
      <phone>507-266-2967</phone>
      <email>Morava-Kozicz.Eva@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kailtin Schwartz, B.S.</last_name>
      <phone>507-293-9114</phone>
      <email>Schwartz.kaitlin@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eva Morava-Kozicz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Edmondson, MD</last_name>
      <phone>215-590-3376</phone>
      <email>EdmondsonA@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth McCormick, MS, LCGC</last_name>
      <phone>267-426-4961</phone>
      <email>McCormickE@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Edmondson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miao He, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgenia Sklirou, MD, FACMG</last_name>
      <phone>412-692-5070</phone>
      <email>SklirouE@chp.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mark Tumblin</last_name>
      <phone>412-692-6472</phone>
      <email>Mark.Tumblin2@chp.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gerard Vockley, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evgenia Sklirou, MD, FACMG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Scaglia, MD, FACMG</last_name>
      <phone>832-822-4280</phone>
      <email>fscaglia@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>May Ali</last_name>
      <phone>832-822-1630</phone>
      <email>maali@bcm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Fernando Scaglia, MD, FACMG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Lam, MD</last_name>
      <phone>206-987-3012</phone>
      <email>Christina.Lam@seattlechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Hayden Vruegdenhil</last_name>
      <phone>206-884-1264</phone>
      <email>Hayden.Vruegndenhil@seattlechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Christina Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <link>
    <url>https://www.rarediseasesnetwork.org/fcdgc</url>
    <description>Frontiers in Congenital Disorders of Glycosylation (FCDGC)</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 8, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Eva Morava-Kozicz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>CDG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Disorders of Glycosylation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data and samples may be shared with other investigators at the discretion of the PI. Only participants who have consented to sharing data/samples will be included in this portion.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Length of study and beyond</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04199000/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04199000/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

